Literature DB >> 17585965

Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms.

Gilberto Fisone1, Kerstin Håkansson, Anders Borgkvist, Emanuela Santini.   

Abstract

The selection and execution of appropriate motor behavior result in large part from the ability of the basal ganglia to collect, integrate and feedback information coming from the cerebral cortex. The GABAergic medium spiny neurons (MSNs) of the striatum represent the main receiving station of the basal ganglia. These cells are innervated by excitatory glutamatergic fibers from cortex and thalamus, and modulatory dopaminergic fibers from the midbrain. MSNs comprise two populations of projection neurons, which give rise to the direct, striatonigral pathway, and indirect, striatopallidal pathway. Changes in transmission at the level MSNs affect the activity of thalamocortical projection neurons, thereby influencing motor behavior. For instance, the cardinal symptoms of Parkinson's disease, such as tremor, rigidity and bradykinesia, are caused by the selective degeneration of dopaminergic neurons originating in the substantia nigra pars compacta, which modulate the activity of MSNs in the dorsal striatum. The therapy for Parkinson's disease relies on the use of levodopa, but is hampered by neuroadaptive changes affecting dopaminergic and glutamatergic transmission in striatonigral neurons. MSNs are also the target of many psychoactive drugs. For example, caffeine affects motor activity by blocking adenosine receptors in the basal ganglia, thereby affecting neurotransmission in striatopallidal neurons. The present review focuses on studies performed in our laboratory, which provide a molecular framework to understand the effects on motor activity of adenosine and caffeine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17585965     DOI: 10.1016/j.physbeh.2007.05.028

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  17 in total

1.  Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia.

Authors:  Hsien-yang Lee; Junko Nakayama; Ying Xu; Xueliang Fan; Maha Karouani; Yiguo Shen; Emmanuel N Pothos; Ellen J Hess; Ying-Hui Fu; Robert H Edwards; Louis J Ptácek
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

2.  PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.

Authors:  Jacquelyn A Brown; Jinbin Xu; Kelly A Diggs-Andrews; David F Wozniak; Robert H Mach; David H Gutmann
Journal:  Exp Neurol       Date:  2011-09-22       Impact factor: 5.330

3.  The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.

Authors:  Alex Martinez; Teresa Macheda; Maria Grazia Morgese; Luigia Trabace; Andrea Giuffrida
Journal:  Neurosci Res       Date:  2011-12-17       Impact factor: 3.304

4.  Combined Effects of Simultaneous Exposure to Caffeine and Cocaine in the Mouse Striatum.

Authors:  Javier A Muñiz; Gimena Gomez; Betina González; María Celeste Rivero-Echeto; Jean Lud Cadet; Edgar García-Rill; Francisco J Urbano; Veronica Bisagno
Journal:  Neurotox Res       Date:  2016-02-08       Impact factor: 3.911

Review 5.  Dopamine and glutamate in Huntington's disease: A balancing act.

Authors:  Véronique M André; Carlos Cepeda; Michael S Levine
Journal:  CNS Neurosci Ther       Date:  2010-04-08       Impact factor: 5.243

6.  The internal state of medium spiny neurons varies in response to different input signals.

Authors:  Zhen Qi; Gary W Miller; Eberhard O Voit
Journal:  BMC Syst Biol       Date:  2010-03-17

7.  The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-03-03       Impact factor: 5.372

8.  Effect of sex on aging-related decline of dopamine transporter in healthy subjects.

Authors:  Seunghyeon Shin; Hyun-Yeol Nam; Myung Jun Lee; Kyoungjune Pak; Keunyoung Kim; In Joo Kim
Journal:  Ann Nucl Med       Date:  2020-10-14       Impact factor: 2.668

Review 9.  Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials.

Authors:  Armando P Signore; Feng Zhang; Zhongfang Weng; YanQin Gao; Jun Chen
Journal:  J Neurochem       Date:  2008-05-03       Impact factor: 5.372

Review 10.  Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.

Authors:  Dénes Zádori; Levente Szalárdy; József Toldi; Ferenc Fülöp; Péter Klivényi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-11-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.